天津医药

• 心血管疾病研究 • 上一篇    下一篇

垠艺TM支架与PARTNER支架治疗急性心肌梗死安全性的比较

王书林   

  1. 天津市胸科医院
  • 收稿日期:2010-10-13 修回日期:2010-10-24 出版日期:2011-01-15 发布日期:2011-01-15
  • 通讯作者: 王书林

Comparison of safety between Yinyi micropole drug coated stents and China made sirolimus-eluting stents for treating patients with acute myocardial infarction

  • Received:2010-10-13 Revised:2010-10-24 Published:2011-01-15 Online:2011-01-15

PDF (PC)

2300

摘要： 目的 探讨垠艺TM微盲孔载药支架在急性心肌梗死(acute myocardial infarction，AMI)经皮冠状动脉介入治疗(percutaneous coronary intervention，PCI)中应用的安全性。方法 连续入选2008年10月至2010年1月期间在天津市南开医院行PCI治疗的AMI患者190例，按植入支架类型分为两组：垠艺TM微盲孔载药支架组（A组，100例）国产雷帕霉素洗脱支架（PARTNER支架）组（B组，90例），对两组患者住院期间、术后30天、术后6个月的主要心血管不良事件（major adverse cardiac events， MACE)、支架内血栓（stents thrombus，ST）发生率进行随访和对比分析。结果 A组无急性、亚急性及晚期血栓发生，B组1例亚急性ST（0 VS 1.1%, P>0.05）。住院期间、术后30天、6个月随访终点时MACE发生率差异无统计学意义（P>0.05）。结论 垠艺TM微盲孔载药支架在治疗AMI中与PARTNER支架一样有较好的安全性。

关键词: 急性心肌梗死, 微盲孔载药支架, 经皮冠状动脉介入治疗

Abstract: 【Abstract】 Objective To investigate the safety of Yinyi micropole drug coated stent after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction．Methods From Oct.2008 to Jan．2010,consecutive patients with AMI underwent PCI were divided into Yinyi micropole drug coated stents group(Group A n=100)and PARTNER stents group(Group B n=90)according to the type of the stents．The incidence of major adverse cardiovascular event(MACE) and stent thrombosis were evaluated during in-hospital 、30days and 6 months follow up after PCI．Results One hundred and ninety patients were successfully treated by PCI .NO in-stent thrombosis was diagnosed in the group A ,while one case stent thrombosis in group B（0 versus 1.1%, P>0.05）.The rates of MACE did not differ significantly between the groups with Yinyi micropole drug coated stents and those PARTNER stents during in-hospital 、30days and 6 months follow up after PCI. Conclusion Implantation of Yinyi micropole drug coated stent after PCI is as safe as PARTNER stents in patients with AMI.

Key words: acute myocardial infarction, micropole drug coated stent, percutaneous coronary intervention